<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Moderna Inc. MRNA, +18.23% soared 19.2% in trading on Monday after the company announced that it began dosing participants in a Phase 1 clinical trial of its experimental HIV vaccine. The trial is an open-label, randomized study evaluating the investigational mRNA vaccine in 100 adults between the ages of 18 and 55 years who are HIV negative.
...read full article on Market Watch
